An interventional study of Mindfulness-Based Stress Reduction in Hidradenitis Suppurativa (HS), sponsored by University of California, San Francisco. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Other
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 103rd largest by enrollment of the 139 interventional ones that give a count, is one of 17 that started in 2026, is one of 27 with no phase, reaches primary completion later than 12 of the 54 other live ones, and was the 161st registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,170 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
University of California, San Francisco has 4 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hidradenitis suppurativa (HS) is a chronic inflammatory condition that causes painful, recurring abscesses and nodules. It is associated with psychological stress and impaired quality of life. Our study aims to pilot a mindfulness-based stress reduction program tailored to patients with HS, then use their feedback to improve the program.
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease characterized by painful skin abscesses, nodules, and scarring. Patients with HS experience significant psychological distress and difficulty coping with disease-related stigma, social isolation, and the daily burden of symptoms, including chronic pain.
Mindfulness-Based Stress Reduction (MBSR) has demonstrated improvements to psychological distress and chronic pain among patients with chronic inflammatory diseases. However, the standard MBSR course may be challenging for individuals with HS due to the location of painful skin lesions in body fold areas and may not adequately address HS-specific stressors.
Our study will adapt the MBSR intervention for HS using a synthesis of published literature on HS-related stressors and coping strategies, participant feedback, and the expertise of a certified MBSR instructor. The intervention will be delivered virtually over Zoom and evaluated through surveys and focus group discussions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mindfulness-Based Stress Reduction
Behavioral: Mindfulness-Based Stress Reduction
An 8-week structured educational program delivered entirely online over Zoom. Participants will meet once weekly for 2.5 hours each session and participate in one seven-hour guided retreat between weeks 6 and 7. All classes include didactic content and mindfulness practices. There is also weekly home-based practice in between sessions. Adaptations include centering group discussion on HS, modifications to the sequence that mindfulness practices are introduced in the program, and options for shorter duration of mindfulness practices.
Also known as: MBSR
Acceptability of MBSR for Individuals with HS as Assessed by the Acceptability of Intervention Measure (AIM)
This tool measures the acceptability of a given intervention. Questions range from 1 to 4. The total score range is 4 to 20. Higher scores indicate greater acceptability of the intervention.
Time frame: 8 weeks
Acceptability of MBSR for Individuals with HS as Assessed by the Theoretical Framework of Acceptability (TFA)
This tool measures the acceptability of a given intervention and has been adapted to fit the needs of our HS study. This tool has 7 Constructs + 1 General Acceptability Construct, however we did not include the Ethical construct due ambiguity regarding the applicability of the construct to the study (i.e., 6 Constructs + 1 General Acceptability Construct). Questions range from 1 and 5. The total mean score range for our adapted TFA is 6 to 30, and for the General acceptability item is 1 to 5. Higher scores indicate greater acceptability of the intervention.
Time frame: 8 weeks
Intervention Adherence as Assessed by MBSR Course Attendance
Intervention adherence will be measured by the percentage of participants who attended at least six of the eight group sessions.
Time frame: 8 weeks
Study Retention as Assessed by the Percent of Participants who Complete the Study
Study retention will be measured by the number of participants who completed survey assessments at the 8-week follow-up time-point divided by the number of participants who enrolled in the study, multiplied by 100.
Time frame: 8 weeks
Feasibility of MBSR for Individuals with HS as Assessed by the Feasibility of Intervention Measure (FIM)
This tool measures the feasibility of a given intervention. Questions range from 1 to 4. The total score range is 4 to 20. Higher scores indicate greater feasibility of the intervention.
Time frame: 8 weeks
Pain Visual Analog Scale
A simple, one-dimensional measurement tool used to rate the intensity of a patient's pain. Range is 0 to 10. Higher scores indicate greater pain. The reported outcome is the change in Visual Analog Scale score from baseline to 8 weeks.
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Brief-COPE (Coping Orientation to Problems Experienced)
This questionnaire is designed to measure the effective and ineffective methods the respondent uses to cope with stressors. Questions range from 1 to 4. The total score range is 28 to 112. There are three overarching sub-scales: * The Problem-Focused Coping range is 8 to 32. * The Emotion-Focused Coping range is 12 to 48. * The Avoidant Coping range is 8 to 32. Higher scores in each sub-scale indicate greater extent of using those methods to cope with stressors. The reported outcome is the change in Brief-COPE sub-scale score from baseline to 8 weeks.
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Perceived Stress Scale
This questionnaire measures the degree to which situations in one's life are appraised as stressful. Questions range from 0 to 4. The total score range is 0 to 40. Higher scores indicate higher perceived stress. The reported outcome is the change in Perceived Stress Scale scores from baseline to 8 weeks.
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Five Facet Mindfulness Questionnaire - Short Form
The 5 facets are Observing, Describing, Detaching, Acting mindfully, and Loving yourself. Each individual facet is given a score from summing up questions related to that facet. This gives insight into the patient's mindfulness in the past month. Questions range from 1 to 5. Higher scores indicate more frequent actions relating to the facet title. For example, a higher score in "Observing" translates to the respondent being more observant and paying attention to their surroundings. The reported outcome is the change in Five Facet Mindfulness Questionnaire scores from baseline to 8 weeks.
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Dermatology Life Quality Index
The DLQI is designed for use in patients over the age of 16 and provides insight into how the respondent's skin condition(s) has affected their life over the last week. Questions range from 0 to 3. The total score range is 0 to 30. Higher scores indicate a greater effect the skin condition(s) has on the respondent's life. The reported outcome is the change in Dermatology Life Quality Index scores from baseline to 8 weeks.
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Hidradenitis Suppurativa Quality of Life
This questionnaire is designed to measure how Hidradenitis Suppurativa has impacted the respondent over the past 7 days. Questions range from 0 to 4. The total score range is 0 to 68. There are three sub-scales: * The symptom score range is 0 to 16. * The activity-adaptation score range is 0 to 32. * The psychosocial score range is 0 to 20. Severity thresholds for the HiSQOL total score were identified for None, Mild, Moderate, Severe, and Very Severe, respectively: 0-4, 5-14, 15-21, 22-23, and ≥24 Severity thresholds for HiSQOL subscales for None, Mild, Moderate, Severe, and Very Severe, respectively: * Symptoms: 0-2, 3-4, 5-6, 7, and ≥8; * Activities-adaptations: 0-1, 2-4, 5-8, 9-12, and ≥13; * Psychosocial: 0, 1, 2, 3-5, and ≥6
Time frame: Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
Of 25 interventional studies with no phase under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →